Harpoon Phase 1 Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH

 

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy
• At the 12 mg dose, cohorts demonstrated favorable activity and safety profile:
  • 63% ORR; with 53% VGPR or better
  • CRS reported in 16% of patients, no Grade 3 events, no ICANS
• Findings support further clinical development at the 12 mg RP2D

https://www.biospace.com/article/releases/harpoon-therapeutics-presents-hpn217-phase-1-clinical-data-in-relapsed-refractory-multiple-myeloma-rrmm-at-ash-2023-and-announces-selection-of-recommended-phase-2-dose-rp2d-/